Researchers in Lebanon found that a cannabis oil extract slowed cancer cell growth and triggered cell death in laboratory tests, but its effects have not been tested in animals or humans.
Researchers at Lebanese American University found that an experimentally prepared extract of Lebanese cannabis oil inhibited the growth of lung and breast cancer cells in laboratory dishes.
The study, published November 15, 2026, in Integrative Cancer Therapies, was conducted entirely in vitro, meaning no animals or people were treated.
Cannabis Extract Slowed Cancer Cell Growth
Researchers tested the extract against two human cancer cell lines: breast cancer (MDA-MB-231) and lung cancer (A549).
The extract produced IC50 values of 26.7 µg/mL for breast cancer cells and 30.2 µg/mL for lung cancer cells, compared with 42.31 µg/mL in noncancerous rat stem cells used for comparison.
The lower IC50 values indicate that the two tested cancer cell lines were more sensitive to the extract than the comparator cells under these laboratory conditions. This does not establish cancer-specific selectivity or safety in living organisms.
Researchers Observed Cell Death and Reduced Migration
At concentrations of 20 and 40 µg/mL, the extract increased apoptosis, or programmed cell death.
Researchers observed increased BAX and cleaved caspase-3 proteins, reduced Bcl-2 levels and decreased cancer cell migration, particularly in lung cancer cells.
The cells also showed extensive cytoplasmic vacuolization after 24 to 48 hours, while reactive oxygen species levels decreased.

Findings Remain Limited to Laboratory Cells
This study does not demonstrate that cannabis oil treats or cures cancer.
The findings come exclusively from laboratory cell cultures. No animal experiments or human clinical trials were conducted.
The research is also separate from the same group's 2024 study examining Lebanese CBD and THC.
Further research would be necessary to determine whether these laboratory effects have any medical relevance.
Sources
- Shebaby et al., Integrative Cancer Therapies, November 15, 2026 (PubMed PMID 43034904) Link
Read next
Cornell and USDA Scientists Publish a Genome-Wide Genotyping Tool for Cannabisarticles · Nov 12, 2026
First EUDA Drug Survey Finds Cannabis Easiest to Obtain as Europeans Split on Regulationarticles · Nov 14, 2026
Nepal Supreme Court Orders Regulated Cannabis Cultivation for Medical and Industrial Usearticles · Nov 15, 2026
Bedrocan Founding Family Wins Backing for Restart, but Financing Remains Unfinishedarticles · Nov 13, 2026
- Shebaby et al., Integrative Cancer Therapies, November 15, 2026 (PubMed PMID 43034904).
0 comments